ArticleInfectious diseases and therapy2026
Diagnostic Performance and Cost-Effectiveness of BALF mNGS in Older Adults with Pulmonary Infections.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionPulmonary infections in elderly patients cause high morbidity and mortality. Conventional culture has low sensitivity and slow turnaround, delaying targeted therapy. Metagenomic next-generation sequencing (mNGS) is an emerging technology, but its diagnostic performance and cost-effectiveness are unclear. This study therefore aims to evaluate its diagnostic performance compared to conventional culture in older adults with pulmonary infections and to assess its cost-effectiveness.
methodsFrom March 2020 to March 2023, 522 patients (aged 55-69 years) diagnosed with pulmonary infections were enrolled at Peking University Shenzhen Hospital. Of these, 168 patients underwent simultaneous mNGS and conventional culture testing using bronchoalveolar lavage fluid (BALF) samples, while the remaining 354 patients received culture testing alone. Pathogen detection results were compared to assess the diagnostic performance of mNGS versus traditional culture methods. Additionally, cost-effectiveness analyses of the two diagnostic strategies-as well as the impact of mNGS testing timing post-admission-were conducted in the overall cohort and across stratified subgroups.
resultsAmong the 168 patients who underwent both tests, mNGS identified a greater diversity and abundance of microorganisms than culture (overall detection: 89.88% vs. 26.79%; pathogen detection: 67.86% vs. 18.45%, p < 0.001). mNGS testing yielded a net economic benefit of 1202.70 CNY per patient overall and 3831.15 CNY among pathogen-positive cases. Delaying mNGS testing tended to be associated with increased hospitalization length of stay (LOS) and costs, with the most pronounced difference observed around 6 days after admission (p < 0.001). Early mNGS testing (within 6 days of admission) provided a net benefit of 6346.00 CNY.
conclusionsBALF-based mNGS showed higher positivity rates and a broader pathogen detection spectrum compared to conventional culture methods in this study. Early implementation of mNGS shows strong potential to guide the treatment of pulmonary infections and reduce healthcare costs for elderly and aging patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.